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Abstract
This report describes a patient suffering from panic disorder who developed repeated suicidal
ideation specifically due to the treatment with Venlafaxine. A first suicide attempt years ago
occurred while being treated with Venlafaxine. Subsequent treatment with SSRIs or other
antidepressants involved no suicidal ideation. Re-commencement of Venlafaxine four years later
immediately led to a second suicide attempt. This unwanted effect subsided immediately after
switching to another SNRI (i.e. Duloxetine). The case report underlines the importance of onset
of suicide risk in panic disorders due to specific antidepressants.
Introduction
Since the introduction of the first specific serotonin
reuptake inhibitors (SSRI) Fluoxetine, a concern emerged
regarding the risk of developing suicide ideation as a rare
side effect [1]. During 2003, Britain's Committee on
Safety of Medicines issued a warning about the dangers of
developing suicide as side effect, first for Paroxetine and
then extended the warning to all the new antidepressants
[2]. The USA Food and Drug Administration followed,
embracing the warning for children, and then extended
the warning to adults [3].
Most of the case reports that were published on the sub-
ject dealt with depressive patients. Some of these case
reports described treatment-resistant patients or patients
who were treated with higher than common-practice drug
doses. All these drawbacks limited the ability to reach con-
clusive answers regarding the true connection between
suicide and antidepressant treatment [4].
The following description of a patient is unique because
he suffered from anxiety disorder and was neither
depressed nor experiencing suicide ideation prior to the
beginning of the antidepressant treatment. This case high-
lights the idiosyncratic response of suicidal ideation
emerging from the treatment with antidepressants.
Case presentation
We report on a 19 year-old-male patient who suffers from
panic disorder according to the DSM-IV (Diagnostic and
Statistical Manual of Mental Disorders, version IV) [5] cri-
teria since the age of 15. He was also diagnosed with co-
morbid narcissistic personality disorder, but without any
drug or alcohol abuse in the past. No medical or other
health problems were known or present. Onset of panic
attacks was at age 15 when his parents divorced. Initial
pharmacological treatment with Fluoxetine 20 mg (titered
up within a few weeks) was combined with individual
and family psychotherapy on an outpatient level. Due to
lack of response the patient was switch to Fluvoxamine
150 mg after 2 months. Despite this intensified treatment
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regimen, panic attacks continued and his overall state
deteriorated eventually leading to hospitalization to a
youth inpatient ward. Treatment was changed to Venla-
faxine initially with 75 mg/day in the morning. Almost
immediately the patient experienced frequent suicide
thoughts along with feelings of despair and hopelessness.
The thoughts frightened him to the point of suffering fre-
quent panic attacks. This deterioration was interpreted as
a sign of treatment resistance and therefore, Venlafaxine
was titered up to 300 mg/day. Subsequently, the patient
made his first suicide attempt by drinking acid that was
left by a careless hospital worker. No psychosocial factors
or stressful life events were detected to have contributed to
the suicide attempt.
Following this event, Paroxetine was trialed up to 20 mg/
d leading to almost full remission and only rare panic
attacks during the following 4 weeks. At that point in
time, when the patient was discharged home, his general
functioning was normal. In the next 4 years the patient
continued on Paroxetine 20 mg/d because when he tried
lowering this dose according to his psychiatrist, he felt
more anxious. He was regularly followed-up during this
time and experienced rare classic panic attacks mostly dur-
ing stressful times.
After 4 years of continuous antidepressant treatment with
Paroxetine, the patient started to complain about delayed
ejaculation which was attributed to Paroxetine. As a con-
sequence other antidepressants were trialed, none of
which improved his sexual disturbance or caused any
worsening of his anxiety. Finally when Venlafaxine was
trialed again due to lack of effective alternatives with no/
little side-effects, the patient complained about frequent
suicide thoughts after one week of Venlafaxine XR 75 mg.
Other medication was not used at that time. He appeared
in the outpatient clinic as very anxious, reported being
afraid to stay on his own, was terrified that he might lose
control and to unintentionally harm himself. The suicidal
thoughts were experienced in the same way as the suicidal
ideation and suicide attempt from his adolescent years.
After switching to Duloxetine 60 mg/day, the suicidal
thoughts completely disappeared.
Discussion
In the last years, several large retrospective analyses were
carried out in order to expand the understanding of the
phenomenon of suicidal ideation due to SSRI medication.
These studies pointed out that regarding the risk of devel-
oping suicide acts, the new antidepressants present with a
similar risk of suicidal ideation as the old TCA, [6,7]. It
was also concluded that antidepressants as a group elevate
the risk for suicide compared to placebo [8].
On the other hand, many studies confirm the reciprocal
connection between the increased use of antidepressants
and the decline of suicide. For example, in a study con-
ducted in Scandinavia, victims of suicide were compared
to people who died as a result of natural or traumatic
events. The suicide group was relatively undertreated with
antidepressants [9]. A more recent report applying aggre-
gated data suggests that the increased use of SSRIs is
related to decreased suicide rates whereas TCA prescrip-
tions were related to increased suicide rates [10]. On a
similar point, a retrospective analyses of the relationship
between prescriptions of SSRIs and suicide rates suggests
that the decrease of SSRI prescriptions for children and
adolescents, both in the United States and the Nether-
lands, after U.S. and European regulatory agencies issued
warnings about a possible suicide risk with antidepressant
use in pediatric patients, was associated with increases in
suicide rates in children and adolescents [11].
Combining this research the conclusion is that for the
society as a group, the use of antidepressants is beneficial.
Nevertheless, for certain individuals, these medicines
could cause suicide ideation and put them in great risk
[12]. Therefore, identifying these patients is important
from a clinical and legal perspective.
The raising awareness of the suicidal risk for developing
suicidal ideation and behavior during treatment with anti-
depressants causes a dramatic change of the attitude
toward these drugs. The presented case demonstrates for
the first time a recurrence of suicidality following antide-
pressants in patients with anxiety disorder. Therefore, sui-
cidality as a direct consequence of antidepressant
treatment is not restricted to patients with major depres-
sive disorder. Improved understanding of the risks and
detection of early clinical warning signs while using anti-
depressants is therefore vital for these patients.
The understanding of the precise mechanisms by which
antidepressants may cause suicidality is still lacking. Few
theories were put forward along the years that can be
divided into two groups: either attributed to depressive
symptoms or attributed to the drug itself. Theories about
attribution to depressive symptoms claimed that this phe-
nomenon is merely a consequence of a clinical worsening
of the specific disorder which is known as the "paradoxi-
cal suicide" [12,13]. Others speculated that these patients
may suffer from an undiagnosed bipolar disorder [14].
Theories that focus on side effect of the drug claimed that
the development of akathisia due to antidepressant treat-
ment possibly is the cause for suicidality [15]. Beyond
these explanations, our case contributes to other theories
as follows. Idiosyncratic response to psychotropic agents
might have occurred in both susceptible individuals as
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the same class. This theory gains more strength when con-
sidering that even treatment of normal subjects could
result in suicide ideation [4]. Furthermore, a sudden onset
of suicidal feelings is a well known but still relatively
underestimated and not widely understood phenome-
non. Patients often describe feelings of hopelessness and
despair that may develop after starting treatment with an
antidepressant [12] that may lead to suicidality. The clas-
sical action of the reserpin can serve as a model for such
action. In addition, auto-aggressive feelings are possibly
part of panic attacks as reported by George et al. who
described three patients developing auto-aggressive and
suicidal thought during panic attacks [16]. The authors
described the suicidal ideation as sudden "attacks" resem-
bling panic attacks.
Hypothetically, biological alterations in the serotonergic
system might have contributed to the suicidal ideation/
attempt in the presence of an SSRI whereas this effect
ceased with the pure NSRI was used. The following mech-
anism for a reduced serotonergic activity induced by SSRI
can be suggested as an explanation of our case observa-
tion. It is reported that the increase of the concentration of
5-HT in the extracellular brain space through most antide-
pressants by preventing its reuptake is offset by a negative
feedback operating at the 5-HT cell-body level [17]. It was
shown that the inhibition of 5-HT reuptake produced by
administration of SSRIs can cause a marked enhancement
of the extracellular concentration of 5-HT in the midbrain
raphe nuclei [18-20] and accounted for the suppression of
5-HT cell firing [21,22]. Consequently, the presence of an
SSRI can lead to a reduced activity of serotonin-mediated
neuronal activity possible related to abnormal behaviour
such as suicidal ideation. Unfortunately, since it was not
possible to clarify the biological/serotonergic make-up of
our case, these assumptions require further investigations.
Conclusion
Nearly all research on suicide rates that show biological
[23], psychological [14,24] and social [25] factors that
contribute to suicide risk, do not differentiate explicitly
between risk for depression and anxiety disorders. More
specifically, little attention has been given to and no clin-
ical experience reported, if modern antidepressants do
contribute to suicide risk in anxiety disorders [4]. More
clarity on the diagnosis specific suicide risk appears to be
important for clinical practice and also for the under-
standing of the underlying mechanisms of suicide risk due
to antidepressants. An enhanced understanding of the
anxiety specific suicide risk might help to improve clinical
practice to anticipate and early identify individuals devel-
oping suicidal ideation while treated with antidepres-
sants.
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